Bluebird bags EU conditional marketing authorisation for Zynteglo
The authorisation for the inherited blood disorder marks bluebird’s first ever drug approval.
Read More
Tag: Zynteglo
Bluebird’s Zynteglo kicks off first Amsterdam CHMP recommendations
The European Medicines Agency’s CHMP positive opinions are sparse this time around.
Read More
- UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies
- Calla Lily Clinical Care begins dosing in trial of intravaginal platform for threatened miscarriage
- Palisade Bio reports phase 1a/b data showing colon‑targeted exposure
- MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours
- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
